Pharma BD Deal Intelligence
Takeda's $5.2B acquisition of Ariad gave it oncology and hematology assets in a straightforward bolt-on deal. With no upfront-split disclosed and no fetched detail on named products, the deal reads as a solid strategic fit rather than a transformative bet.
Takeda acquired Ariad for $5.2B for oncology and hematology divisions.
Takeda announced acquisition of all outstanding shares in ARIAD for $24 per share in cash, enterprise value of approximately $5.2 billion, gaining brigatinib…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda acquired Ariad for $5.2B for oncology and hematology divisions.
9K US cases/yr · $5.6B Global CML Market (2017) · ~95% 5-Year CML Survival with TKIs
Takeda expanded Iclusig's label to include frontline Ph+ ALL (in combination with chemotherapy) via the PhALLCON trial. The OPTIC trial established a response-based dose-reduction strategy that improved arterial occlusive event safety while preserving efficacy in resistant/intolerant CML. Competitors include Novartis (Gleevec/Tasigna), BMS (Sprycel), Pfizer (Bosulif), and newer BCR-ABL allosteric inhibitor asciminib (Scemblix, Novartis).
Takeda expanded Iclusig's label and grew revenues to $700M+. The OPTIC trial established optimized dosing with improved safety.
$24/share for Iclusig (ponatinib) and investigational brigatinib. Part of Takeda Pharmaceutical Co.'s $5.2B deal to acquire Ariad Pharmaceuticals.
Takeda Pharmaceutical Co. completed its acquisition of Ariad Pharmaceuticals for $5.2B. Takeda acquired Ariad for $5.2B for oncology and hematology divisions.
Accelerated approval for ALK+ NSCLC after crizotinib. First FDA approval for pipeline.
Expanded indication for newly diagnosed Ph+ ALL, broadening commercial potential.
See timeline for full assessment. Assessment of Takeda Pharmaceutical Co.'s $5.2B acquisition of Ariad Pharmaceuticals and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals (this deal) | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2003 deals · Takeda Pharmaceutical Company Ltd. deals · Oncology deals